Comparison of the chronic toxicity of piroxantrone, losoxantrone and doxorubicin in spontaneously hypertensive rats

Toxicology

Volumn 128, Issue 1, 1998, Pages 35-52

  Herman, Eugene H ^a   Zhang, Jun ^a   Hasinoff, Brian B ^b   Tran, Khanh T ^b   Chadwick, Douglas P ^a   Clark Jr , John R ^c   Ferrans, Victor J ^c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Cardiotoxicity; Doxorubicin; Electronmicroscopy; Iron complexes; Losoxantrone; Nephrotoxicity; Piroxantrone; Reactive oxygen species

Indexed keywords

DOXORUBICIN; IRON; LOSOXANTRONE; OXANTHRAZOLE; REACTIVE OXYGEN METABOLITE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CARDIOTOXICITY; CELL VACUOLE; CHRONIC TOXICITY; CLINICAL CHEMISTRY; CONTROLLED STUDY; DOSE RESPONSE; HEART; HEART INJURY; HEART MUSCLE INJURY; HISTOLOGY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; KIDNEY INJURY; MALE; MICROSCOPY; MOLECULAR MODEL; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SARCOPLASMIC RETICULUM; SMALL INTESTINE; SPONTANEOUSLY HYPERTENSIVE RAT; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; ANTHRAQUINONES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BLOOD CHEMICAL ANALYSIS; BODY WEIGHT; DOXORUBICIN; FERRIC COMPOUNDS; HEART DISEASES; HYPERTENSION; INTESTINES; KIDNEY DISEASES; MALE; MYOCARDIUM; PYRAZOLES; PYRAZOLONES; RATS; RATS, INBRED SHR; RATS, INBRED WKY;

EID: 0032568897     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(98)00049-3     Document Type: Article

References (36)

1. Allen, A., Wolf, M., Crawford, E.D., Davis, M.P., Natale, R.B., Barnett, M.L., 1992. Phase II evaluation of piroxantrone in renal cell carcinoma. A southwest oncology group study. Invest. New Drugs 10 (2), 129-132.
2. Ames, M.M., Loprinzi, C.L., Collins, J.M., et al., 1990. Phase I and clinical pharmacological evaluation of piroxantrone hydrochloride (oxantrazole). Cancer Res. 50 (13), 3905-3909.
3. Billingham, M.E., 1991. Role of endomyocardial biopsy in diagnosis and treatment of heart disease. In: Silver, M.D. Jr. (Ed.), Cardiovascular Pathology. Churchill Livingstone, New York, pp. 1465-1486.
4. Bogusch, G., 1975. Electron microscopic investigations on leptomeric fibrils and leptomeric complexes in the hen and pigeon heart. J. Mol. Cell Cardiol. 7, 733-745.
5. Burke, J.F. Jr., Laucius, J.F., Brodovsky, H.S., Soriano, R.Z., 1977. Doxorubicin hydrochloride-associated renal failure. Arch. Intern. Med. 137, 385-388.
6. Calvert, A.H., Smith, I., Jones, A., et al., 1994. Phase II study of losoxantrone in previously treated and untreated patients with advanced breast cancer (CA). Proc. Am. Soc. Clin. Oncol. 13, 71.
7. Doroshow, J.H., 1996. Anthracyclines and anthracenediones. In: Chabner, B.A., Longo, D.L. (Eds.), Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott-Raven, Philadelphia, pp. 409-434.
8. Ferrans, V.J., Sanchez, J.A., Herman, E.H., 1992a. Role of myocardial biopsy in the diagnosis of anthracycline toxicity. In: Muggia, F.M., Green, M.D., Speyer, J.L. (Eds.), Cancer Treatment and The Heart. The Johns Hopkins University Press, Baltimore, pp. 198-216.
9. Ferrans, V.J., Sanchez, J.A., Herman, E.H., 1992b. Pathologic anatomy of animal models of anthracycline-induced cardiotoxicity. In: Muggia, F.M., Green, M.D., Speyer, J.L. (Eds.), Cancer Treatment and The Heart. The Johns Hopkins University Press, Baltimore, pp. 89-113.
10. Foster, B.J., Newell, D.R., Graham, M.A., et al., 1992. Phase I trial of the anthrapyrazole Cl-941: prospective evaluation of a pharmacokinetically guided dose-escalation. Eur. J. Cancer 28 (2-3), 463-469.
11. Frank, P., Novak, R.F., 1986. Effects of anthrapyrazole anti-neoplastic agents on lipid peroxidation. Biochem. Biophys. Res. Comm. 140 (3), 797-807.
12. Gianni, L., Myers, C.E., 1992. The role of free radical formation in the cardiotoxicity of anthracycline. In: Muggia, F.M., Green, M.D., Speyer, J.L. (Eds.), Cancer Treatment and The Heart. The John Hopkins University Press, Baltimore, pp. 9-46.
13. Gogas, H., Mansi, J.L., 1996. New drugs. The anthrapyrazoles. Cancer Treat. Rev. 21 (6), 541-552.
14. Graham, M.A., Newell, D.R., Butler, J., Hoey, B., Patterson, L.H., 1987. The effect of the anthrapyrazole antitumour agent Cl-941 on rat liver microsome and cytochrome P-450 reductase mediated free radical processes. Inhibition of doxorubicin activation in vitro. Biochem. Pharmacol. 36 (20), 3345-3351.
15. Graham, M.A., Newell, D.R., Foster, B.J., Calvert, A.H., 1989. The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug Cl-941 in the mouse: a guide for rational dose escalation in patients. Cancer Chemother. Pharmacol. 23 (1), 8-14.
16. Hantel, A., Donehower, R.C., Rowinsky, E.K., et al., 1990. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole. Cancer Res. 50 (11), 3284-3288.
17. Hasinoff, B.B., 1989a. The interaction of the cardioprotective agent ICRF-187 (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin. Agents Actions 26, 378-385.
18. Hasinoff, B.B., 1989b. Self-reduction of the iron(III)-doxorubicin complex. Free Radic. Biol. Med. 7 (6), 583-593.
19. Herman, E.H., Ferrans, V.J., Ardalan, B., El-Hage, A.N., 1985. Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats. Toxicol. Appl. Pharmacol. 78, 202-214.
20. Herman, E.H., El-Hage, A., Ferrans, V.J., 1988. Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats. Toxicol. Appl. Pharmacol. 92, 42-53.
21. Herman, E.H., Zhang, J., Hasinoff, B.B., Clark, J.R. Jr., Ferrans, V.J., 1997. Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex. J. Mol. Cell Cardiol. 29 (9), 2415-2430.
22. Ingle, J.N., Kuross, S.A., Mailliard, J.A., et al., 1994. Evaluation of piroxantrone in women with metastatic breast cancer and failure of nonanthracycline chemotherapy. Cancer 74 (6), 1733-1738.
23. Judson, I.R., 1992. The anthrapyrazoles: a new class of compounds with clinical activity in breast cancer. Semin. Oncol. 19 (6), 687-694.
24. Lown, J.W., Chen, H.H., Plambeck, J.A., Acton, E.M., 1979. Diminished superoxide anion generation by reduced 5-iminodaunorubicin relative to daunorubicin and the relationship to cardiotoxicity of the anthracycline antitumor agents. Biochem. Pharmacol. 28 (17), 2563-2568.
25. Myers, C.E., Muindi, J.R., Zweier, J., Sinha, B.K., 1987. 5-lminodaunomycin. An anthracycline with unique properties. J. Biol. Chem. 262 (24), 11571-11577.
26. Novak, R.F., Kharasch, E.D., Frank, P., Runge-Morris, M., 1988. Anthracyclines, anthracenediones and anthrapyrazoles: comparison of redox cycling activity and effects on lipid peroxidation and prostaglandin production. In: Lown, J.W. (Ed.), Anthracycline and Anthracenedione-Based Anticancer Agents. Elsevier, Amsterdam, pp. 475-526.
27. Posner, L.E., Dukart, G., Goldberg, J., Bernstein, T., Cartwright, K., 1985. Mitoxantrone: an overview of safety and toxicity. Invest. New Drugs 3, 123-132.
28. Ravdin, P.M., Green, S., Doroshow, J.H., Martino, S., 1994. Phase II trial of piroxantrone in metastatic breast cancer. A southwest oncology group study. Invest. New Drugs 12 (4), 333-336.
29. Savarese, D.M., Denicoff, A.M., Berg, S.L., et al., 1993. Phase I study of high-dose piroxantrone with granulocyte colony-stimulating factor. J. Clin. Oncol. 11 (9), 1795-1803.
30. Showalter, H.D., Johnson, J.L., Werbel, L.M., Leopold, W.R., Jackson, R.C., Elslager, E.F., 1984. 5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]ipyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation. J. Med. Chem. 27 (3), 253-255.
31. Showalter, H.D., Fry, D.W., Leopold, W.R., Lown, J.W., Plambeck, J.A., Reszka, K., 1986. Design, biochemical pharmacology, electrochemistry and tumour biology of anti-tumour anthrapyrazoles. Anticancer Drug Des. 1 (2), 73-85.
32. Talbot, D.C., Smith, I.E., Mansi, J.L., Judson, I., Calvert, A.H., Ashley, S.E., 1991. Anthrapyrazole C1941: a highly active new agent in the treatment of advanced breast cancer. J. Clin. Oncol. 9 (12), 2141-2147.
33. Walsh, S.M., Walley, V.M., Chandra, L., Huan, S.D., Veinot, J.P., Higginson, L.A., 1995. Potential cardiotoxicity with the use of DuP-941: a case report. Can. J. Cardiol. 11 (5), 419-422.
34. Zalupski, M.M., Benedetti, J., Balcerzak, S.P., et al., 1993. Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas. A southwest oncology group study. Invest. New Drugs 11 (4), 337-341.
35. Zhang, J., Herman, E.H., Ferrans, V.J., 1993. Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin, with or without ICRF-187. Am. J. Pathol. 142, 1916-1926.
36. Zhang, J., Clark, J.R., Herman, E.H., Ferrans, V.J., 1996. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187. J. Mol. Cell Cardiol. 28 (9), 1931-1943.